IA
ALXO icon

IndexIQ Advisors’s ALX Oncology ALXO Stock Holding History

IndexIQ Advisors’s Portfolio ALXO Stock Details ALXO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		$374K Buy
+22,127
New +$378K 0.01% 918

Other funds holding ALXO

VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

IndexIQ Advisors's ALXO Position: Q1 2022 in Review

IndexIQ Advisors opened a new position in ALX Oncology (ALXO) in Q1 2022: 22,127 shares worth $374K. The stake represents 0.01% of the portfolio and ranks #918 among its holdings.

96 funds tracked by Wall St. Rank hold ALXO as of Q1 2022.

  • IndexIQ Advisors held 22,127 shares of ALX Oncology worth $374K as of Q1 2022.
  • ALX Oncology was a new IndexIQ Advisors position in Q1 2022.
  • ALX Oncology made up 0.01% of IndexIQ Advisors's portfolio in Q1 2022, its #918 holding.
  • 96 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2022.

Based on IndexIQ Advisors's 13F filing for Q1 2022, filed 6 May 2022.